Monitor shareholder vote on the business combination and FDA decision on MyoVista wavECG. The deal's success hinges on Zcash price stability and regulatory approvals; any delay or rejection could send HSCS back to pre-deal levels.
Price Chart
Executive Summary
HeartSciences reported no meaningful revenue for fiscal year 2026, with $1.7M cash and $0.2M equity, while announcing a transformative all-stock business combination with Fortitude Mining Holdings, a Zcash miner. The deal would issue ~107.6M shares to DCG and create a combined entity with $70M pro forma equity, offering a potential exit from its struggling medtech operations.
Key Facts
- No meaningful revenue reported for fiscal year ended April 30, 2026
- Cash and cash equivalents of approximately $1.7 million as of April 30, 2026
- Shareholders' equity of $0.2 million as of April 30, 2026
- Proposed all-stock business combination with Fortitude Mining Holdings, a Zcash mining operator
- Pro forma combined total shareholders' equity of $70.0 million
- Issuance of approximately 107.6 million shares of Class V Common Stock to Digital Currency Group (DCG)
- Reverse stock split proposal authorized within a range of 1-for-2 to 1-for-5 to support Nasdaq listing
- Fortitude mined 72,696 ZEC in six months ended June 30, 2026, representing ~28% of overall ZEC production
- Fortitude estimates run-rate Adjusted EBITDA over $50 million at Zcash prices above $500
- MyoVista Insights platform commercially launched with deployment contracts; MyoVista wavECG device under FDA 510(k) review
Financial Impact
Pro forma combined equity of $70M vs current market cap of $9M implies significant potential upside, though deal completion and Zcash price volatility are key risks
Risk Factors
- Business combination may not receive shareholder approval or satisfy closing conditions
- Nasdaq listing requirements for the combined company may necessitate a reverse stock split, diluting existing holders
- Zcash price volatility directly impacts Fortitude's projected EBITDA and the combined company's valuation
- FDA 510(k) clearance for MyoVista wavECG is uncertain and could affect the standalone value if the deal fails
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-082577 |
| Document: ea0299627-8k_heart.htm | 0001213900-26-082577 |
| Document: 0001213900-26-082577-index-headers.html | 0001213900-26-082577 |
| Document: 0001213900-26-082577-index.html | 0001213900-26-082577 |
| Document: 0001213900-26-082577.txt | 0001213900-26-082577 |
| 8-K Data (Synthetic) | 0001213900-26-082577 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | DEFA14A | — | awaiting T+1 | — | — |
Oct 26, 2026 today | DEFA14A | — | awaiting T+1 | — | — |
Oct 23, 2026 2d ago | SC 13D/A | $3.41 | awaiting T+1 | — | $3.18 (−6.74%) |
Oct 21, 2026 5d ago | DEFA14A | $3.17 $3.14 | ▼ −0.95% | ▼ −0.42% | $3.18 (+0.32%) |
Oct 19, 2026 7d ago | DEFA14A | $3.13 $3.56 | ▲ +13.74% | ▲ +13.21% | $3.18 (+1.60%) |
Oct 19, 2026 7d ago | DEFA14A | $3.07 $3.13 | ▲ +1.95% | ▲ +1.62% | $3.18 (+3.58%) |
Oct 19, 2026 7d ago | DEFM14A | $3.07 $3.13 | ▼ −1.95% | ▼ −1.62% | $3.18 (−3.58%) |
Oct 15, 2026 11d ago | DEFA14A | $3.02 $3.07 | ▲ +1.66% | ▲ +1.23% | $3.18 (+5.30%) |
Oct 9, 2026 17d ago | 424B5 | $3.30 $3.09 | ▲ +6.36% | ▲ +6.35% | $3.18 (+3.64%) |
Oct 6, 2026 20d ago | DEFA14A | $3.49 $3.04 | ▼ −12.89% | ▼ −12.47% | $3.18 (−8.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers